REVELATION BIOSCIENCES, INC. Quarterly Debt-to-equity in % from Q2 2021 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Revelation Biosciences, Inc. quarterly Debt-to-equity history and growth rate from Q2 2021 to Q2 2024.
  • Revelation Biosciences, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 105 %, a 20.1% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 105 +17.6 +20.1% Jun 30, 2024
Q1 2024 57.3 -143 -71.4% Mar 31, 2024
Q4 2023 64.2 -1.65K -96.2% Dec 31, 2023
Q3 2023 72.1 -11K -99.3% Sep 30, 2023
Q2 2023 87.2 -1.33K -93.8% Jun 30, 2023
Q1 2023 200 -30.2 -13.1% Mar 31, 2023
Q4 2022 1.71K +1.61K +1524% Dec 31, 2022
Q3 2022 11K +10.9K +10152% Sep 30, 2022
Q2 2022 1.42K +1.31K +1170% Jun 30, 2022
Q1 2022 230 Mar 31, 2022
Q4 2021 105 Dec 31, 2021
Q3 2021 108 Sep 30, 2021
Q2 2021 112 Jun 30, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.